Filter by faculty:

Found 5 matching student topics

Displaying 1–5 of 5 results

Developing a precision oncology workflow for Osteosarcoma treatment

Osteosarcoma (OS) is the most common malignant bone tumour that primarily affects children and adolescents. With approximately 400 diagnosed cases/year in Australia, OS has the lowest survival rate of all solid cancers and is the leading cause of cancer-related death in Queensland adolescents. Unfortunately, 3 in 4 patients will not survive longer than five years following diagnosis with metastatic OS. Clinical “one size fits all” treatment strategies results in highly variable and unacceptably poor patient responses. Shockingly, both the OS …

Study level
PhD, Master of Philosophy
Faculty
1043076
School
School of Biomedical Sciences
Research centre(s)
Centre for Biomedical Technologies

Targeting a novel adaptive neovascular response of the tumour microenvironment to treat advanced prostate cancer

Prostate cancer (PCa) is a significant healthcare burden in Australia. Androgen signalling inhibition using androgen receptor (AR) antagonists is the principal systemic therapy for advanced PCa. Androgen receptors (AR) are an attractive therapeutic target due to their elevated expression in tumour epithelial cells and the retention of androgen signalling throughout the disease continuum.However, patients eventually develop resistance to treatment, and PCa cells metastasise to distant bone and visceral organs, representing an incurable stage of the disease. Understanding mechanisms that contribute …

Study level
PhD, Master of Philosophy, Honours
Faculty
1043076
School
School of Biomedical Sciences

Eribulin effects on epithelial mesenchymal plasticity and therapy response

This proposal builds on data showing reversal of TGFbeta- or 5FU-induced epithelial mesenchymal transition (EMT) in breast cancer cell lines in vitro and in vivo by eribulin (1, 2). Given the established relationship between EMT and therapy resistance in a wide range of scenarios (3-5), this potential of eribulin to reverse EMT and sensitise breast cancer cells to therapy has wide-reaching implications for improved patient outcomes. Evidence for this potential at the therapeutic level has been seen with in vitro …

Study level
Master of Philosophy, Honours
Faculty
Faculty of Health
School
School of Biomedical Sciences

Investigating the role of Neuropilin-1 in Triple-Negative Breast Cancer metastasis and chemoresistance

Triple-negative breast cancers (TNBC) are negative for Estrogen Receptor, Progesterone Receptor and HER2 expression, are clinically aggressive and are unresponsive to the available hormonal or targeted drugs used for other breast cancer subtypes, so that TNBC patients rely mainly on chemotherapy. TNBC accounts for 15-20% of all invasive breast cancer and patients have increased risk of recurrence, mortality and early metastatic progression. Thus, there is an urgent clinical need to develop improved treatment strategies for TNBC. Neuropilin-1 (NRP1) is a …

Study level
PhD, Master of Philosophy, Honours
Faculty
1043076
School
School of Biomedical Sciences

Understanding capsular polysaccharide diversity is key to next generation therapies for multi-drug resistant Acinetobacter baumannii infections

Bacteriophage therapy is an attractive innovative treatment for infections caused by extensively drug resistant Acinetobacter baumannii, for which there are few effective antibiotic treatments remaining.Capsular polysaccharide (CPS) is a primary receptor for lytic bacteriophage, thus knowledge of the chemical structures of CPS produced by the species underpins the identification of suitable phage for therapeutic cocktails.As many phage depolymerases cleave a specific CPS linkage formed by either a glycosyltransferase or polymerase enzyme, characterisation of these proteins are essential.However, these remain largely …

Study level
PhD
Faculty
1043076
School
School of Biomedical Sciences
Research centre(s)

Centre for Immunology and Infection Control

Page 1 of 1